The study, published in the Journal of Clinical Oncology found that the 5-year survival with ipilimumab (18.2%) was double that with placebo (8.8%) and roughly double the historical survival rate of patients with stage IV melanoma (approximately 10%).
Among patients with advanced melanoma, twice as many survived to 5 years if they received ipilimumab plus dacarbazine than if they received placebo plus dacarbazine as part of a phase 3 randomized clinical trial, according to a report published online February 23 in the Journal of Clinical Oncology.
The investigators described their analysis as the first examination of long-term survival after a course of ipilimumab therapy, as well as the first analysis of safety outcomes in a small subset of patients who continued to receive ipilimumab as maintenance therapy. They performed this milestone survival analysis “to confirm prior reports of long-term survival in a proportion of patients from nonrandomized phase II studies,” and their findings do in fact confirm those reports, said Dr Michele Maio of University Hospital of Siena (Italy) and her associates.
Link to the article on Oncology Practice:
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen